Episode 68
Biotech Hangout
00:00
The Uncertainty Around Rata
The expectation around Sage are definitely more mixed for the street, but all of that is sort of a head scratcher. And it's always interesting to me how people sort of parse what a CEO is saying. Now, again, I think it's totally fine. They did Rata. We're excited about that. That would be a great contributor. But we agree. We definitely want the drug to be approved. The FD has a hurdle to make sure that multiple studies hit the primary endpoints clearly with statistical significance and meanfulness. So that was one part of the uncertainty. Any one of us can guess what it will be. You put these proboscals because we don't know
Transcript
Play full episode
